Clinical study of intratumoral dendritic cell injection after radiofrequency ablation therapy in hepatitis C virus-related hepatocellular carcinoma patients

Clinical study of intratumoral dendritic cell injection after radiofrequency ablation therapy in hepatitis C virus-related hepatocellular carcinoma patients - Combination of RFA and intratumoral DC injection for the treatment of HCC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000451

Enrollment

Registered

2006-07-24

Start date

2006-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Intratumoral DC injection (Once a week, 4times)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HCV-related hepatocellular carcinoma patients whom principle investigator or co-investigator judged to be completely cured by radiofrequency ablation therapy, and who meet the following conditions: - 20 years or more - Performance status 0-1 - No serious abnormality in bone marrow, liver and/or renal functions

Exclusion criteria

Exclusion criteria: Patients who have: uncontrolled infections, active autoimmune diseases, serious cardiac disease and other cancers; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Rate of relapse, relapse-free survival, tumor markers, immunological parameters	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026